Compare Exelixis, Inc. (EXEL) vs Vertex Pharmaceuticals Incorporated (VRTX) Stock

Exelixis, Inc. (EXEL) offers the better valuation at 15.8x trailing P/E (13.3x forward), making it the more compelling value choice. Analysts rate Exelixis, Inc. (EXEL) a "Buy" — based on 32 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, Exelixis, Inc. (EXEL) is the cheapest at 15.8x versus Vertex Pharmaceuticals Incorporated at 32.4x. On forward P/E, Exelixis, Inc. is actually cheaper at 13.3x. The PEG ratio (P/E divided by earnings growth rate) is the most growth-adjusted single valuation metric: Exelixis, Inc. wins at 0.26x versus Vertex Pharmaceuticals Incorporated's 3.10x — a PEG below 1.0 traditionally signals the market is underpricing earnings growth.

Over the past 5 years, Vertex Pharmaceuticals Incorporated (VRTX) delivered a total return of +136.2%, compared to +97.6% for Exelixis, Inc. (EXEL). A $10,000 investment in VRTX five years ago would be worth approximately $24K today (assuming dividends reinvested). Over 10 years, the gap is even starker: EXEL returned +1110% versus VRTX's +481.2%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Vertex Pharmaceuticals Incorporated (VRTX) is the lower-risk stock at 0.44β versus Exelixis, Inc.'s 0.63β — meaning EXEL is approximately 42% more volatile than VRTX relative to the S&P 500. On balance sheet safety, Exelixis, Inc. (EXEL) carries a lower debt/equity ratio of 8% versus 20% for Vertex Pharmaceuticals Incorporated — giving it more financial flexibility in a downturn.

Exelixis, Inc. (EXEL) is the more profitable company, earning 33.7% net margin versus 32.9% for Vertex Pharmaceuticals Incorporated — meaning it keeps 33.7% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: VRTX leads at 39.1% versus 37.6% for EXEL. At the gross margin level — before operating expenses — EXEL leads at 96.6%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

The PEG ratio (forward P/E divided by expected earnings growth rate) is the most precise measure of undervaluation relative to growth potential. By this metric, Exelixis, Inc. (EXEL) is the more undervalued stock at a PEG of 0.26x versus Vertex Pharmaceuticals Incorporated's 3.10x. A PEG below 1.0 is traditionally considered the threshold for growth-adjusted undervaluation. On forward earnings alone, Exelixis, Inc. (EXEL) trades at 13.3x forward P/E versus 25.7x for Vertex Pharmaceuticals Incorporated — 12.4x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for VRTX: 9.7% to $545.08.

None of the stocks in this comparison currently pay a material dividend. All are effectively zero-yield and should be held for capital appreciation rather than income.

For long-horizon retirement investors, Exelixis, Inc. (EXEL) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.63), +1110% 10Y return). Both have compounded well over 10 years (EXEL: +1110%, VRTX: +481.2%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both. In terms of investment character: EXEL is a mid-cap deep-value stock; VRTX is a mid-cap quality compounder stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.